Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Reimbursement Business Strategies Deals

Novartis Sees Reimbursement Advantage For PCSK9 Launch

  • Analysis

Executive Summary

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

You may also be interested in...



It Has Been A Long Farewell To The Medicines Company

The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.

Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo

The move follows a similar price cut for Amgen's competing PCSK9 inhibitor Repatha and comes as PBMs, including UnitedHealth Group's OptumRx, are looking for ways to maintain the drug rebate status quo.

Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda

CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model. 
Table

View full table

Topics

Related Companies

Tags:
Reimbursement Business Strategies Deals
UsernamePublicRestriction

Register

SC141241

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By